Literature DB >> 7507735

Glycosyl-phosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria: partial or complete defect in an early step.

J Norris1, S Hall, R E Ware, T Kamitani, H M Chang, E Yeh, W F Rosse.   

Abstract

The defect in the biosynthesis of the glycosyl-phosphatidyl inositol (GPI) anchor in paroxysmal nocturnal hemoglobinuria (PNH) appears to be in the initial steps. In biosynthetic studies using [3H]mannose, abnormal granulocytes of eight patients, and B lymphocytes transformed by Epstein-Barr virus of six different patients synthesized dolichyl phosphoryl mannose, but little or no later mannosylated intermediates. When fused with murine cell lines known to be deficient at different biosynthetic steps of the GPI anchor, the GPI-anchor-deficient granulocytes of 21/21 patients and lymphocytes from 6/6 patients complemented all murine cell lines except those of class A; cells of this class are not able to add N-acetylglucosamine to phosphatidylinositol. These studies indicate that the defect in GPI-anchor synthesis in PNH is early in the pathway, and is the same as that of class A mutants, but may be partial in some patients, resulting in the production of small amounts of mannosylated intermediates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507735

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

Review 1.  The genetic defect of PNH.

Authors:  T Kinoshita
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

Review 2.  Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidylinositol anchor.

Authors:  E T Yeh; W F Rosse
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 3.  Complement receptors and regulatory proteins: immune adherence revisited and abuse by microorganisms.

Authors:  J P Atkinson; M Krych; M Nickells; D Birmingham; V B Subramanian; L Clemenza; J Alvarez; K Liszewski
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

4.  A novel G6PD mutation leading to chronic hemolytic anemia.

Authors:  Jenny McDade; Tatiana Abramova; Nicole Mortier; Thad Howard; Russell E Ware
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.